Brufau Cochs, MagíAlamon Reig, FrancescLuque Luna, MarBosch Amate, XavierMoreta, Maria JoséBassegoda, OctaviMascaró Galy, José Manuel2024-12-192024-12-192023-10-131610-0379https://hdl.handle.net/2445/217206Dipeptidyl-peptidase 4 inhibitors (DPP4i) are widely used hypoglycemic drugs strongly associated with bullous pemphigoid (BP), the most common autoimmune subepidermal blistering disease. DPP4i-associated BP may display differences in histological, immunological, and clinical features. Here we present the case of a patient treated with DPP4i who developed a severe BP involving both the skin and esophagus.3 p.application/pdfengcc by-nc (c) Brufau Cochs, Magí, et al., 2023https://creativecommons.org/licenses/by-nc/4.0/DermatologiaDiabetisPèmfigDermatologyDiabetesPemphigusinfo:eu-repo/semantics/article7517602024-12-19info:eu-repo/semantics/openAccess38286622